Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Michael Carulli, Chief Financial Officer of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), sold 28,249 shares of common stock on July 1, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a price of $1.0647, for a total transaction value of $30,076. The stock has shown strong momentum recently, gaining over 10% in the past week. According to InvestingPro analysis, PMVP is currently trading below its Fair Value.
Following the transaction, Carulli directly owns 60,146 shares of PMV Pharmaceuticals.
The sale was executed to cover tax obligations related to the vesting of restricted stock units (RSUs).
In other recent news, PMV Pharmaceuticals, Inc. held its virtual 2025 Annual Meeting of Stockholders, where several key proposals were voted on by shareholders. The election of Class II Directors resulted in Arnold Levine, Ph.D., and Charles M. Baum, M.D., Ph.D., being elected to serve until the 2028 annual meeting. Levine received 26,723,192 votes in favor, while Baum garnered 13,258,337 votes in favor. A non-binding advisory vote on the compensation of the company’s named executive officers was not approved, with 11,646,401 votes in favor and 20,170,398 against. Additionally, the proposal to ratify Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was approved, with 39,963,653 votes in favor. These developments are part of the company’s ongoing governance and operational activities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.